This pattern was not observed in bioimpedance-derived “Fluid Overload” analyses, raising the hypothesis that SGLT2 inhibition may have additional antihypertensive effects that are more prominent in patients with diabetes, and which are distinct from their diuretic effects (possibly through effects on vascular stiffness or endothelial function).43, –45 The lack of measured effect of empagliflozin on adiposity is consistent with its modest effects on glycated hemoglobin observed in CKD populations. Here, SLC5A2 is linked to chronic kidney disease.